Business
-
Transpire Bio, which previously announced deals with Recipharm for development of four inhaled products, announced a new deal with INTO (Inhalation Together) for development of three additional inhaled products: TRB-5, TRB-6 and TRB-7. INTO is… Read more . . .
-
Odyssey Health has announced the creation of a subsidiary called Odyssey Neuropharma that will develop intranasal drugs for the treatment of neurological disorders, including PRV-002 intranasal synthetic neurosteroid for the treatment of concussion. In addition to… Read more . . .
-
Blue Water Vaccines said that it intends to develop its BWV-201 intranasal Streptococcus pneumoniae vaccine candidate for the prevention of non-invasive pneumococcal pneumonia. The company is already developing the live attenuated intranasal vaccine, which it licensed… Read more . . .
-
Dutch intranasal vaccine developer and CDMO Intravacc said that it has received an award of up to $14.6 million from the US National Institute of Allergy and Infectious Diseases (NIAID) to support development of an… Read more . . .
-
Pfizer has completed its acquisition of Biohaven Pharmaceutical, including Biohaven’s intranasal zavegepant (BHV-3500) calcitonin gene-related peptide (CGRP) receptor antagonist, the company said. Pfizer announced that it had acquired the ex-US rights to zavegepant and Nurtec… Read more . . .
-
Startup inhaled drug developer AeroRx Therapeutics and nebulizer maker HCmed Innovations have announced that they will partner on development of a nebulized LABA/LAMA inhalation solution for the treatment of COPD. AeroRx is a spinoff of… Read more . . .
-
After announcing a deal with Recipharm for development of two inhaled drugs (TRB-1 and TRB-2) earlier this year, Transpire Bio says that it has signed an agreement with the CDMO for development of an additional… Read more . . .
-
Ocugen announced that it has acquired US, European, and Japanese rights to an intranasal COVID-19 vaccine developed at Washington University in St. Louis. In September 2020, Bharat Biotech announced that it had acquired rights to… Read more . . .
-
According to Qnovia, which recently changed its name from Respira Technologies, the company has closed a $17 million Series A financing round led by Blue Ledge Capital, with the funds intended to support development of… Read more . . .
-
RS BioTherapeutics, which recently announced positive results from a proof of concept study of its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) in a mouse model, said that the company has raised $3 million in a Seed… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK